Diagnosis and management of bronchiolitis obliterans syndrome following lung or hematopoietic cell transplantation

Expert Review of Respiratory Medicine

Volumn 10, Issue 6, 2016, Pages 599-602

  Meyer, Keith C ^a,b  

^a Pulmonary and Critical Care Medicine   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

bronchiolitis obliterans syndrome; hematopoietic cell transplantation; lung transplantation; obliterative bronchiolitis; treatment

Indexed keywords

AZITHROMYCIN; FLUTICASONE; FLUTICASONE PROPIONATE; MONTELUKAST; NINTEDANIB; PIRFENIDONE; PREDNISONE;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBODY MEDIATED REJECTION; BRONCHIOLITIS OBLITERANS; BRONCHOSCOPY; CHRONIC GRAFT VERSUS HOST DISEASE; CORTICOSTEROID THERAPY; EDITORIAL; EXERCISE; FORCED EXPIRATORY VOLUME; GRAFT DYSFUNCTION; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LUNG BIOPSY; LUNG FUNCTION TEST; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; LUNG VOLUME; MONOTHERAPY; MULTICENTER STUDY (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RESIDUAL VOLUME; RETRANSPLANTATION; SLOW VITAL CAPACITY; SPIROMETRY; VITAL CAPACITY;

EID: 84961393620     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2016.1162717     Document Type: Editorial

References (20)

1. G.C.Hildebrandt, T.Fazekas, A.Lawitschka, et al. Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD. Bone Marrow Transplant. 2011 Oct;46(10):1283–1295.
2. B.K.Au, M.A.Au, J.W.Chien Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011 Jul;17(7):1072–1078.
3. K.C.Meyer, G.Raghu, G.M.Verleden, et al. An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. Eur Respir J. 2014 Dec;44(6):1479–1503.
4. M.H.Jagasia, H.T.Greinix, M.Arora, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015 Mar;21(3):389.e1–401.e1. doi:10.1016/j.bbmt.2014.12.001. Epub 2014 Dec18.
5. G.M.Verleden, G.Raghu, K.C.Meyer, et al. A new classification system for chronic lung allograft dysfunction. J Heart Lung Transplant. 2014 Feb;33(2):127–133.
6. S.E.Verleden, D.Ruttens, E.Vandermeulen, et al. Restrictive chronic lung allograft dysfunction: where are we now? J Heart Lung Transplant. 2015 May;34(5):625–630.
7. T.Martinu, D.N.Howell, R.D.Davis, et al. Pathologic correlates of bronchiolitis obliterans syndrome in pulmonary retransplant recipients. Chest. 2006 Apr;129(4):1016–1023.
8. M.Arora, C.S.Cutler, M.H.Jagasia, et al. Late acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015 Nov 2. pii:S1083-8791(15)00707-7. doi:10.1016/j.bbmt.2015.10.018. [Epub ahead of print].
9. R.Vos, B.M.Vanaudenaerde, S.E.Verleden, et al. Anti-inflammatory and immunomodulatory properties of azithromycin involved in treatment and prevention of chronic lung allograft rejection. Transplantation. 2012 Jul 27;94(2):101–109.
10. B.C.Norman, D.A.Jacobsohn, K.M.Williams, et al. Fluticasone, azithromycin and montelukast therapy in reducing corticosteroid exposure in bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: a case series of eight patients. Bone Marrow Transplant. 2011 Oct;46(10):1369–1373.
11. K.M.Williams, G.-S.Cheng, I.Pusic, et al. Fluticasone, azithromycin, and montelukast treatment for new-onset bronchiolitis obliterans syndrome after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015 Oct 22. pii:S1083-8791(15)00679-5. doi:10.1016/j.bbmt.2015.10.009. [Epub ahead of print].
12. P.A.Corris, V.A.Ryan, T.Small, et al. A randomised controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantation. Thorax. 2015 May;70(5):442–450.
13. R.Vos, B.M.Vanaudenaerde, S.E.Verleden, et al. A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation. Eur Respir J. 2011 Jan;37(1):164–172.
14. D.Ruttens, S.E.Verleden, E.Vandermeulen, et al. Prophylactic azithromycin therapy after lung transplantation: post hoc analysis of a randomized controlled trial. Am J Transplant. 2015 Aug 4. doi:10.1111/ajt.13417. [Epub ahead of print].
15. K.-W.Jo, S.Yoon, J.W.Song, et al. The efficacy of prophylactic azithromycin on bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Int J Hematol. 2015 Sep;102(3):357–363.
16. F.Ihle, W.von Wulffen, C.Neurohr. Pirfenidone: a potential therapy for progressive lung allograft dysfunction? J Heart Lung Transplant. 2013 May;32(5):574–575.
17. E.Calore, P.Marson, M.Pillon, et al. Treatment of acute graft-versus-host disease in childhood with extracorporeal photochemotherapy/photopheresis: the padova experience. Biol Blood Marrow Transplant. 2015 Nov;21(11):1963–1972.
18. C.Del Fante, T.Galasso, P.Bernasconi, et al. Extracorporeal photopheresis as a new supportive therapy for bronchiolitis obliterans syndrome after allogeneic stem cell transplantation. Bone Marrow Transplant. 2016 Jan 4. doi:10.1038/bmt.2015.324. [Epub ahead of print].
19. M.Greer, M.Dierich, C.De Wall, et al. Phenotyping established chronic lung allograft dysfunction predicts extracorporeal photopheresis response in lung transplant patients. Am J Transplant. 2013 Apr;13(4):911–918.
20. S.E.Verleden, J.L.Todd, M.Sato, et al. Impact of CLAD phenotype on survival after lung retransplantation: a multicenter study. Am J Transplant. 2015 Aug;15(8):2223–2230.